IPSEN, OOO
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1929-01-01
- Employees
- 5.7K
- Market Cap
- $9.8B
- Website
- https://www.ipsen.com/
Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines
- Conditions
- Moderate to Severe Glabellar Lines
- Interventions
- Biological: Botulinum toxin type ADrug: Placebo
- First Posted Date
- 2015-02-03
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 185
- Registration Number
- NCT02353871
- Locations
- 🇫🇷
Mediti, Juan les Pins, France
🇫🇷Nouvelle Clinique Bel Air, Bordeaux, France
🇩🇪Hautzentrum am Starnberger See, Starnberg, Germany
Patient and Physician's Satisfaction After a Long Term Treatment of Glabellar Lines With Dysport®
- Conditions
- Glabellar Lines
- First Posted Date
- 2015-02-03
- Last Posted Date
- 2020-11-05
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 150
- Registration Number
- NCT02353897
- Locations
- 🇦🇺
ERASE, Malvern, Australia
🇰🇿Laser Center DARUS, Almaty, Kazakhstan
🇨🇿BcD Clinic s.r.o., Praha, Czechia
Study to Assess Impact of Dysport Injections Early After Stroke on Upper Limb Spasticity Progression
- Conditions
- StrokeUpper Limb Spasticity
- Interventions
- Biological: Botulinum toxin type ADrug: Placebo
- First Posted Date
- 2014-12-22
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 42
- Registration Number
- NCT02321436
- Locations
- 🇲🇾
Neurology Laboratory -University Malaya Medical Centre, Kuala Lumpur, Malaysia
🇵🇭Center for Neurodiagnostic and Therapeutic Services Metropolitan Medical Center, Manila, Philippines
🇸🇬TTSH Rehabilitation Centre Ang Mo Kio Community Hospital, Singapore, Singapore
EGb 761® (Tanakan®) Effectiveness in the Treatment of Patients of Middle Age and Younger With Psycho-emotional Symptoms, Added to Cognitive Disorders
- Conditions
- Cognitive Disorders
- Interventions
- Drug: EGb761®
- First Posted Date
- 2014-12-22
- Last Posted Date
- 2020-03-31
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 54
- Registration Number
- NCT02321475
- Locations
- 🇷🇺
Russian National Research Medical University, Moscow, Russian Federation
🇷🇺First Moscow State Medical University, Moscow, Russian Federation
Efficacy, Safety and Tolerability of Eziclen in Adult Subjects Undergoing Colonoscopy
- First Posted Date
- 2014-12-22
- Last Posted Date
- 2019-03-04
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 296
- Registration Number
- NCT02321462
- Locations
- 🇷🇺
Federal State Budgetary Institution "State Scientifical Center of Coloproctology", Moscow, Russian Federation
🇷🇺State Healthcare Institution of Yaroslavl Region "Regional Clinical Cancer Hospital", Yaroslavl, Russian Federation
🇷🇺State Healthcare Institution Municipal Clinical Hospital No. 31 of Moscow, Moscow, Russian Federation
The Effectiveness of Circadin in Improving Quality of Sleep in Patients Aged 55 or Over
- Conditions
- Insomnia
- First Posted Date
- 2014-12-22
- Last Posted Date
- 2019-01-11
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 40
- Registration Number
- NCT02321449
- Locations
- 🇷🇺
State research center of preventive medicine, Moscow, Russian Federation
🇷🇺Research and Education Center of Moscow State University named after M.V. Lomonosov, Moscow, Russian Federation
🇷🇺First Moscow State Medical University, Moscow, Russian Federation
ETREAT Study on Effectiveness of Botulinum Toxin Type A Injections to Treat Post-stroke Upper and/or Lower Limb Spasticity
- Conditions
- Spasticity
- First Posted Date
- 2014-10-27
- Last Posted Date
- 2019-08-16
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 110
- Registration Number
- NCT02275312
Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction
- First Posted Date
- 2014-10-27
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 52
- Registration Number
- NCT02275338
- Locations
- 🇧🇪
Ste-Elisabeth Hospital, Brussels, Belgium
Study To Assess Renewal Of Treatment In Patients Recently Diagnosed With Prostate Cancer
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2019-07-25
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 368
- Registration Number
- NCT02238366
Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease Patients
- Conditions
- Huntington's Disease
- Interventions
- Drug: BN82451BDrug: Placebo
- First Posted Date
- 2014-09-04
- Last Posted Date
- 2019-01-15
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 17
- Registration Number
- NCT02231580